Pricing Log in Create free account
Friday 6 November 2026 Export BVS’s income statement to Excel — free account

Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024.

Revenue
+2.73%
EPS
+100.6%
Free cash flow
−31.4%
Total debt
−28.8%

Quarter to September 2026, against a year earlier

10.51 0.17 −1.59%
Market cap
$899.9M
P/E
12.3×
Fwd P/E
17.2×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.18
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — — 1 — — — — — — — —
Insider Ownership 30.72%

Capital & Financial Ratios $m

Size
Market Cap 899.91
Revenue ttm 585.64
Net income ttm 64.33
Free cash flow ttm 84.99
Net debt Q 199.12
Valuation
P/E 12.32
Forward P/E 17.20
Price / sales 1.24
Forward P/S Powerpack
Price / FCF 8.53
Price / book 2.48
Financial health
Current ratio Q 1.68 (at or above 1.5: strong)
Debt / equity Q 0.79
Interest coverage Q 2.58
Growth
Revenue growth Q +2.73% (above 0%: growing)
Operating income growth Q −13.78% (below 0%: shrinking)
EPS, this year +12.94%
EPS, next year A +15.60% (at or above 15%: strong)
Revenue, next year A −25.03% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +15.01% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 1.5×; over the ten years it ranged from 0.5× in 2021 to 2.5× in 2022.
P/S against its own 10 years 68.49%
10-year low 10-year high
P/B against its own 10 years 62.53%
10-year low 10-year high
EV/Sales against its own 10 years 55.86%
10-year low 10-year high
EV/FCF against its own 10 years 10.38%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 37 42 51 31
Receivables 123 127 128 138
Inventory 91 92 82 83
Other — — — —
268 276 273 266
2023 2024 2025 Q'26
Payables 23 24 11 26
ST’ Debt 28 27 15 19
Other 5 23 4 4
175 210 160 158

Compound Annual Growth %

10y 5y 3y
Sales — 12.08% 3.52%
Cash Flow — 0.79% 0.00%
Earnings — 6.73% 0.00%
Book Value — 9.64% (17.86%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.17 Actual 0.17

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.22 0.24 Beat by 0.02
Q1 FY26 0.09 0.15 Beat by 0.06
Q2 FY26 0.22 0.22 Met by 0.00
Q3 FY26 0.17 0.17 Met by 0.00
Q4 FY26 0.25 — Reports 4 March 2027

EPS $

Mar Jun Sep Dec Year
’26 0.04 0.47 0.09 — —
’25 (0.04) 0.11 0.05 0.21 0.33
’24 (0.07) (0.37) (0.07) 0.00 (0.56)
’23 (2.24) (0.06) (0.12) (0.10) (2.49)
’22 (0.19) (0.11) (1.76) (0.52) (2.59)
’21 0.19 (0.10) 0.05 0.57 (0.15)
’19 — — 0.07 — (0.01)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 132 153 142 — —
’25 124 148 139 158 568
’24 129 151 139 154 573
’23 119 137 121 135 512
’22 117 140 129 126 512
’21 82 110 109 130 431
’20 79 58 86 99 321
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 9 20 21 — —
’25 (19) 26 30 38 75
’24 (6) 15 10 19 39
’23 2 11 (8) 10 15
’22 (21) 3 (1) 5 (14)
’21 (18) 17 11 13 23
’20 18 8 21 25 72
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 8 19 20 — —
’25 (20) 25 30 37 72
’24 (6) 15 10 19 38
’23 (1) 9 (10) 10 8
’22 (24) 1 (2) 10 (15)
’21 (19) 16 9 4 9
’20 17 7 20 24 55
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 275 319 319 340 321 431 512 512 573 568 586 +8.4% 426 455 484 (5.2%)
Gross margin, % 66.71 73.63 73.63 73.27 72.71 70.25 64.65 64.06 67.72 68.33 68.70 +1.6 pt
EBT (6) 6 6 10 16 9 (189) (121) (52) 26 40 n/m
EBT margin, % (2.06) 1.91 1.91 2.85 4.96 2.20 (36.91) (23.64) (9.13) 4.53 6.85 +6.6 pt
Net income (7) 0 (12) 6 15 10 (213) (196) (47) 27 64 n/m
Per share, $
Per share, $ Revenue 4.83 65.14 65.14 5.99 5.65 9.48 8.34 8.18 8.88 8.53 8.56 +6.5%
Earnings (0.41) — — (0.01) — (0.15) (2.59) (2.49) (0.56) 0.34 0.86 n/m
Cash flow 0.65 0.00 9.22 0.72 1.26 0.51 (0.22) 0.24 0.60 1.12 1.28 +6.2%
Capex 0.00 0.00 (0.52) (0.04) (0.29) (0.30) (0.02) (0.12) (0.02) (0.04) (0.04) n/m
Free cash flow 0.65 0.00 8.70 0.68 0.97 0.21 (0.24) 0.13 0.59 1.08 1.24 +5.8%
Book value 0.00 0.00 0.00 2.56 2.54 11.74 6.71 3.53 2.88 3.43 4.27 n/m
Shares, m 57 5 5 57 57 45 61 63 65 67 68 +1.8%
Valuation, ×
Valuation, × P/E 21.92 21.92 21.92 21.92 21.92 32.43 0.00 0.00 0.00 21.88 12.32 16.4
P/S 0.29 0.29 0.29 0.29 0.29 1.53 0.31 0.64 1.18 0.87 1.24 0.6
P/B 0.65 0.65 0.65 0.65 0.65 1.23 0.39 1.49 3.65 2.17 2.48 1.2
EV/Sales 0.61 0.61 0.61 0.61 0.61 2.25 1.07 1.34 1.70 1.30 1.58 1.1
EV/FCF 2.89 2.89 2.89 2.89 2.89 102.14 (36.50) 86.04 25.72 10.24 10.87 20.2
Cash, $m
Cash, $m Operating cash flow 37 0 45 41 72 23 (14) 15 39 75 87 +8.1%
Capex — 0 (3) (2) (17) (14) (1) (7) (1) (3) (2) n/m
Free cash flow 37 0 43 38 55 9 (15) 8 38 72 85 +7.6%
Balance, $m
Balance, $m Working capital — — 83 94 89 82 (31) 93 65 112 108 +4.4%
Net debt — — 152 133 102 308 388 358 294 243 199 +6.9%
Shareholders’ equity — — — 146 144 534 412 221 186 228 292 +7.8%
Returns, %
Returns, % ROA 0.00 (8.12) 0.00 2.90 3.39 2.25 (12.21) (14.31) (4.70) 3.22 8.33 +3.2 pt
ROIC — 0.00 10.49 6.99 5.40 0.89 (13.06) (8.82) (1.98) 7.16 7.22 +7.2 pt
ROE 0.00 0.00 (12.49) 4.71 11.33 5.72 (33.55) (49.34) (17.76) 10.98 22.96 +11.0 pt
People
People Employees — — — 680 700 1,200 1,120 970 930 930 — +5.4%
Revenue/emp, $m 0.00 0.00 0.00 0.50 0.46 0.36 0.46 0.53 0.62 0.61 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Bioventus Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SIBN SiBone $1.1B — (loss-making) — (loss-making) +14.49% (above 0%: growing) n/m +31.13% (above 0%: growing) 79.29% (7.81%) Compare
IRMD iRadimed Corporation $1.1B 44.9× 39.6× +14.15% (above 0%: growing) +15.91% (above 0%: growing) +18.58% (above 0%: growing) 76.26% 33.63% Compare
AHCO AdaptHealth Corp. $1.0B — (loss-making) — (loss-making) +10.90% (above 0%: growing) n/m −23.58% (below 0%: shrinking) 15.40% (20.91%) Compare
CBLL CeriBell, Inc. $1.0B — (loss-making) — (loss-making) +29.89% (above 0%: growing) n/m −19.65% (below 0%: shrinking) 89.77% (70.03%) Compare
BVS Bioventus Inc. $899.9M 12.3× 17.2× +2.73% (above 0%: growing) +100.60% (above 0%: growing) −31.40% (below 0%: shrinking) 68.19% 6.81%
QDEL QuidelOrtho Corporation $880.5M — (loss-making) — (loss-making) −11.57% (below 0%: shrinking) n/m +120.70% (above 0%: growing) 46.79% (1.21%) Compare
BBNX Beta Bionics, Inc. $842.1M — (loss-making) — (loss-making) +30.28% (above 0%: growing) n/m −45.46% (below 0%: shrinking) 57.26% (74.94%) Compare
KIDS OrthoPediatrics Corp. $841.3M — (loss-making) — (loss-making) +18.63% (above 0%: growing) n/m +146.64% (above 0%: growing) 74.28% (5.81%) Compare
INMD InMode Ltd. $771.1M 10.7× 11.8× −0.01% (below 0%: shrinking) −30.95% (below 0%: shrinking) −12.63% (below 0%: shrinking) 74.82% 12.82% Compare
Median of peers $945.3M — — +14.32% — +2.98% 74.55% (6.81%)

All 149 Medical Devices stocks →

Bioventus Inc. (BVS) Latest News

3 Nov

Impact 3 · · Simply Wall St.
Impact 3 · · GuruFocus.com

2 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat
Impact 3 · · GlobeNewswire

27 Oct

Impact 3 · · GlobeNewswire

13 Aug

Impact 4 · · The Motley Fool transcript

10 Aug

Impact 4 ·

6 Aug

Impact 3 · · Moby

5 Aug

Impact 4 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·

22 Jul

Impact 3 ·

8 Jun

Impact 3 · · MarketBeat

14 May

Impact 4 · · Simply Wall St.

8 May

Impact 3 · · Zacks

6 May

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat
Impact 4 · · Zacks
Impact 3 · · GlobeNewswire

5 Mar

Impact 4 · · MarketBeat
Impact 4 · · GuruFocus.com
Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 4 · · Associated Press Finance
Impact 4 · · GlobeNewswire

10 Feb

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

15 Jan

Impact 4 · · MarketBeat

14 Jan

Impact 3 · · Simply Wall St.
stockrow.com/BVS · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com